Ocumension Therapeutics released its Monthly Return for the period ended 31 March 2026, confirming a stable capital structure with no new share issuances, cancellations, or treasury share movements.

Authorised and Issued Capital • Authorised share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001, equivalent to USD 50,000. • Issued shares (excluding treasury shares) closed the month unchanged at 815.38 million, while treasury shares stood at 20.95 million, keeping total issued shares at 836.33 million. • The company affirmed full compliance with Hong Kong Stock Exchange public-float requirements.

Share Option Schemes • Employee Stock Option Plan (2018) held 13.32 million outstanding options, unchanged during the month. • 2021 Share Option Scheme recorded the lapse of 67,047 options, reducing outstanding options to 37.52 million. No options were granted or exercised, resulting in zero proceeds from option exercises.

Share Award Scheme • Under the 2021 Share Award Scheme, 862,300 awards vested and 31,397 lapsed. Unvested awards now cover 10.44 million shares. No new shares were issued or transferred from treasury during the month.

Other Equity Instruments • The company reported no outstanding warrants, convertibles, or other share-linked agreements during the period.

Overall, Ocumension Therapeutics’ March filing reflects steady equity metrics, with authorised and issued share counts unchanged and limited employee incentive-related adjustments.